title: Deterioration of metabolic parameters during short-term psychiatric inpatient treatment: a prospective naturalistic study.
abstract: OBJECTIVE
  To investigate the influence of a single episode of psychiatric inpatient treatment on metabolic parameters.
  
  
  METHODS
  A total of 294 consecutive patients of an Upper Austrian psychiatric department were assessed at admission and discharge regarding bodyweight, body mass index (BMI), high density cholesterol (HDL), low density cholesterol (LDL), triglycerides (TG) and fasting glucose (FG), and the TG/HDL ratio.
  
  
  RESULTS
  Patients showed an increase of BMI of 0.35 kg/m² (+ 1.3%) during a mean duration of inpatient stay of 25.8 days. LDL rose by 10.7 mg/dl (+ 8.1%), triglycerides by 23.0 mg/dl (+ 17%), HDL decreased by 4.4 mg/dl (-7.4%). Fasting glucose decreased by 3.6 mg/dl (-3.8%), yet the TG/HDL ratio, as a marker for insulin resistance, increased significantly from 2.86 to 3.58 (+ 25.2%) on average. Patients with psychotic disorders gained about three times more weight than patients with other diagnoses. Negative alterations of serum lipids were to be found in all diagnostic groups but were especially pronounced in patients with psychotic disorders who were treated with second-generation antipsychotics clozapine, olanzapine and quetiapine.
  
  
  CONCLUSIONS
  Psychiatric inpatient treatment leads to clinically relevant deterioration of metabolic parameters within a short time, most pronouncedly in patients with psychotic disorders.
authors: Department of Psychiatry 1, Landesnervenklinik Wagner-Jauregg, Linz, Austria. hans.rittmannsberger@gespag.at
authors: Hans
authors: H
authors: Rittmannsberger
authors: Johannes
authors: J
authors: Fellinger
authors: Christian
authors: C
authors: Foff
authors: Gertraud
authors: G
authors: Walli
authors: Thomas
authors: T
authors: Zaunmüller
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001317:Austria; D001569:Benzodiazepines / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003024:Clozapine / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000627:therapeutic use; D005260:Female; D005947:Glucose / Q000378:metabolism; D006760:Hospitalization; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology; D007902:Length of Stay; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy / Q000378:metabolism*; D008875:Middle Aged; D015999:Multivariate Analysis; D000077152:Olanzapine; D019338:Polypharmacy; D011446:Prospective Studies; D011567:Psychiatric Department, Hospital; D011618:Psychotic Disorders / Q000188:drug therapy* / Q000378:metabolism; D000069348:Quetiapine Fumarate; D012044:Regression Analysis; D014280:Triglycerides / Q000097:blood; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D015415:Biomarkers; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003987:Dibenzothiazepines; D014280:Triglycerides; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D005947:Glucose; D003024:Clozapine; D000077152:Olanzapine